333780-74-8

Usage

Derivative of benzoic acid

2,3-difluoro-5-iodobenzoic acid is derived from benzoic acid, with modifications to its structure.

Fluorine atoms at positions 2 and 3

Two fluorine atoms are attached to the benzoic acid structure at the 2nd and 3rd positions.

Iodine atom at position 5

A single iodine atom is attached to the benzoic acid structure at the 5th position.

Building block in synthesis

2,3-difluoro-5-iodobenzoic acid is used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.

High stability

The compound is known for its high stability, which makes it suitable for various applications in organic chemistry.

Reactivity

2,3-difluoro-5-iodobenzoic acid is also known for its reactivity, making it a valuable intermediate in organic chemistry.

Development of new materials

The compound is used in the development of new materials, showcasing its versatility in different scientific fields.

Research tool

2,3-difluoro-5-iodobenzoic acid serves as a research tool in various scientific fields, contributing to the advancement of knowledge in chemistry and related disciplines.

Upstream product

• 124-38-9 carbon dioxide 
• 501433-08-5 1,2-difluoro-3,5-diiodobenzene 
• 6148-64-7 ethyl potassium malonate 
• 333780-76-0 Ethyl 3-(2,3-difluoro-5-iodophenyl)-3-oxopropanoate 
• 4519-39-5 2,3-difluorobenzoic acid 
• 501433-06-3 2,3-difluoro-1,4-diiodobenzene 
• 64248-57-3 1-iodo-2,3-difluorobenzene 

Downstream Products

• 333780-76-0 Ethyl 3-(2,3-difluoro-5-iodophenyl)-3-oxopropanoate 
• 1097626-22-6 (2,3-difluoro-5-iodo-phenyl)-methanol 
• 1163692-49-6 methyl 2,3-difluoro-5-iodobenzoate 

Relevant academic research and scientific papers

1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to Aβ plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.

CHEMICAL COMPOUNDS

In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable sa lts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.

MACROLONES - AMINO SUBSTITUTED QUINOLONES

Compounds of formula (I) or pharmaceutically acceptable derivatives thereof having antimicrobial activity are disclosed, as are processes for their preparation, compositions containing them and their use in medicine.

NOVEL 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR

Provision of a compound having an anti-HIV activity, particularly an integrase inhibitory activity.A 4-oxoquinoline compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.The present invention also relates to a pharmaceutical composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; an integrase inhibitor, an antiviral agent, anti-HIV agent and the like, which contains the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof as an active ingredient; an anti-HIV composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and one or more other kinds of anti-HIV activity substances as active ingredients; an anti-HIV agent containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof as an active ingredient, which is used for a multiple drug therapy with other anti-HIV agent(s), and the like.

4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Heterocycle carboxamides as antiviral agents

The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Oxazinoquinolones useful for the treatment of viral infections

The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Thioxazinoquinolones as antiviral agents

The present invention provides a compound of formula I These compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.

The basicity gradient-driven migration of iodine: Conferring regioflexibility on the substitution of fluoroarenes

Six different fluoroarenes were submitted to the same transformations. Direct deprotonation with alkyllithium or lithium dialkylamide as reagents and subsequent carboxylation afforded the acids 1, 6, 11, 16, 18, and 23. If the aryllithium intermediate was trapped with iodine rather than with dry ice, an iodofluoroarene (2, 7, 12, 17, 19, and 24) was formed. This, upon treatment with lithium diisopropylamide, underwent deprotonation and iodine migration. The resulting new aryllithium species was intercepted either by carboxylation, to give the acids 3, 8, 13, 20, and 25, or by neutralization, to produce the iodofluoroarenes 4, 9, 14, 21, and 26. The latter family of compounds was converted into another set of acids 5, 10, 15, 22, and 27 by subsequent treatment with butyllithium or isopropylmagnesium chloride and carbon dioxide. ( Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002).